Drug Profile

Trientine tetrahydrochloride - Orphalan

Alternative Names: Cuprior; Cuvrior; Ke Pei Ou; TETA-4HCl

Latest Information Update: 17 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Orphalan
Developer JACE PHARMA; Orphalan
Class Ethylenediamines; Small molecules
Mechanism of Action Chelating agents

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Hepatolenticular degeneration
New Molecular Entity Yes

Highest Development Phases

Marketed Hepatolenticular degeneration

Most Recent Events

07 Mar 2025 Launched for Hepatolenticular degeneration in China (PO)
07 Mar 2025 Launched for Hepatolenticular degeneration in New Zealand (PO) prior to March 2025
16 Feb 2024 Orphalan completes a phase I trial for pharmacokinetics study in United Kingdom (PO) (NCT06128954)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com